Farletuzumab ecteribulin by Eisai for Ovarian Cancer: Likelihood of Approval

Farletuzumab ecteribulin is under clinical development by Eisai and currently in Phase II for Ovarian Cancer.

Related Posts

Amgen sees highest patent filings and grants during Jul...

Nov 24, 2023

Boehringer Ingelheim plans sustainability work for the ...

Jul 12, 2024

MSD secures worldwide license for LaNova’s LM-299

Nov 15, 2024